Abstrak
Vaginal candidiasis (VC) is one of the most common fungal diseases. It is estimated that three quarters of all adult women worldwide suffer from this condition at some time during their lives, and in many the disease is recurrent. Candida albicans is the most common causative fungus and has been isolated from more than 80% of specimens obtained from women with VC. The prime symptom of this infection is itch, worse at night, and exacerbated by warm climate. Burning vulval discomfort, dysuria, dyspareunia, and vaginal discharge are common accompanying complaints. The absence of a fi shy odor distinguishes the condition from bacterial vaginosis. The discharge is usually thick and cheesy. Diagnosis is made from the presence of fi lamentous forms and spores of Candida seen under microscope. Bacterial vaginosis and trichomoniasis are easily differentiated from candidiasis by microscopy.
1
Ketoconazole has been the fi rst orally active antifungal, the dosage for VC is 200 mg twice daily for 5 days. It is a potent inhibitor of some cytochrome P450 enzymes, particularly CYP3A4, which mediate the metabolism of many drugs and the synthesis and/or metabolism of endogeneous steroids such as cortisol, estradiol and testosterone. It may also increase the level of hepatic enzymes during therapy and hepatotoxicity has been estimated to occur in 0.1 -1.0 % of treated patients.
2
Fluconazole is a newer oral antifungal. It is more potent than ketoconazole against Candida albicans, has less potential to interact with other drugs or steroids, and has little effect on the liver. 3 It is administered as a single oral dose of 150 mg, which produces concentrations in vaginal tissue and secretion within the MIC range for Candida albicans for more than 48 hours. 4 Since fl uconazole 150 mg is considerably expensive, low doses of fl uconazole in combination with low doses of ketoconazole are being tested against Candida albicans in an attempt to substitute the single high dose of fl uconazole with a single dose of the combination, as a therapy of VC with lower cost. Besides cost consideration, combination of 2 different drugs may retard the development of resistance. Although ketoconazole and fl uconazole belong to the same azole antimycotics and therefore may have the same major antimycotic action, these drugs are from different subclasses and hence may have different additional unknown antimycotic actions. These may contribute to the total antimycotic action, and in combination may be expected to delay the emergence of resistant fungi.
An in vitro study by the principal investigator (JS) with an isolate of Candida albicans from a patient with pulmonary disease showed that the MIC of ketoconazole is 1 mcg/ mL and that of fl uconazole is 0.2 mcg/mL. In combination, the MIC of ketoconazole is 1 mcg/mL and that of fl uconazole is 0.1 mcg/mL (unpublished observations). A single dose of 200 mg ketoconazole produces mean peak serum concentration of approximately 3.5 mcg/ mL, 5 while a single dose of 150 mg fl uconazole produces a mean peak serum concentration of 2.6 mcg/mL (range 1.6 -3.6 mcg/mL).
5 Therefore, a combination of 100 mg ketoconazole and 40 mg of fl uconazole produces serum concentrations of ketoconazole and fl uconazole which are higher than the MIC of ketoconazole and much higher than that of fl uconazole.
A preliminary study using a mixture of 100 mg ketoconazole and 40 mg fl uconazole for the treatment of vaginal candidiasis has been carried out. Patients were women who visited the principal investigator (JS)'s private clinic with vaginal discharge as their chief complaint. As part of his daily practice, the investigator took vaginal secretion for direct microscopic examination and vaginal swab for mycological culture. The diagnosis of VC was confi rmed in 11 women and the low-dose combination was administered as a single oral dose. One to 2 weeks after drug administration, the mycological culture was negative in 8 women, positive in 1 woman, while 2 women did not return for follow-up (unpublished observations). The one failure in mycological cure may, based on the investigator's experience, be due to her long fi ngernails that may become the yeast colonization site, which eventually cause reinfection.
6
Since the low-dose combination is meant to substitute the single high dose of fl uconazole in the treatment of VC, the effi cacy and safety of both preparations should be compared in a formal clinical trial with appropriate design and conducted according to GCP (Good Clinical Practice).
The objectives of the present study were to compare the effi cacy and safety of 100 mg ketoconazole and 40 mg fl uconazole combination with 150 mg fl uconazole in single doses for the treatment of proven VC. The effi cacy of the combination was expected to be not inferior compared to that of 150 mg fl uconazole for the treatment of VC.
METHODS

Patients
Female outpatients, aged 18 years or older, with proven VC were recruited into the study. The clinical diagnosis was confi rmed initially by a positive microscopic smear (pseudohyphae and/or yeast cells), and subsequently by a positive pretreatment culture after patient's inclusion. Only symptomatic patients with a minimum of pruritus or burning or excessive discharge, and a positive smear and culture, were eligible for entry into this study.
Excluded from the study were pregnant or lactating women, women with trichomoniasis or bacterial vaginosis (syphilis, gonorrhea, chlamydial infection, Gardnerella vaginalis infection) or nonspecifi c vaginitis, patients with clinically signifi cant renal or hepatic dysfunction, patients with uncontrolled underlying disease such as diabetes mellitus, and patients with known HIV seropositivity or with clinically diagnosed AIDS or its related complex. Also excluded were patients receiving therapy with immunosuppressants (including high doses of long-term corticosteroids), antifungal (including topical agents), rifampicin, barbiturates, carbamazepine or phenytoin, each within the previous 3 weeks. Other exclusions were concurrent therapy with H 2 blockers, proton pump inhibitors, antacids, warfarin or sulfonylureas. Known hypersentivity to azole antifungal agents, history of alcoholism, drug abuse or psychosis, and patients with doubtful compliance were also excluded. These conditions were excluded by anamnesis and routine clinical examination.
The study started in June 2003 and was closed in around July 2007 although the intended sample size had not been reached (sample size estimation: see below). Because most patients with VC had mixed infection with bacterial vaginosis, the protocol was amended in June 2005 to include these patients and they also received doxycycline 2 times 100 mg/day for 5 days.
Study design and procedure
This was a randomized, single-blind (blind investigators), parallel group study, ketoconazole-fl uconazole combination versus fl uconazole, performed in female outpatients with proven VC who visited the private clinic of the principal investigator (JS) and the Obgyn Clinic at Dr. Cipto Mangunkusumo General National Hospital, Jakarta, Indonesia. The study protocol was approved by the Ethics Committee of the Faculty of Medicine, University of Indonesia, Jakarta, and the study was conducted in compliance with Good Clinical Practice. Informed consent was obtained from every patient before screening.
Medical history, physical and gynecological examinations were carried out for each patient before entering the study. A pregnancy test was performed only if pregnancy was suspected.
At the initial examination, a vaginal swab was obtained from each patient with a clinical diagnosis of vulvovaginal candidiasis. The patient may enter the study based on the presence of pruritus, burning, and/or excessive discharge, and a Candida positive microscopic smear, showing the presence of yeast cells or pseudohyphae on the smear. The diagnosis was subsequently confi rmed by a positive culture for Candida. The culture for Candida was partly done at the Parasitology Laboratory, Faculty of Medicine, University of Indonesia, and partly at Exacta Laboratory, the private laboratory of the principal investigator.
The investigational product, capsules containing ketoconazole 100 mg and fl uconazole 40 mg combination, and the comparator, fl uconazole 150 mg capsules (Difl ucan ® 150, PT Pfi zer Indonesia) were provided by PT Kalbe Farma, Jakarta. Treatment allocation was according to block-randomization using random permuted blocks of size 8.
Eligible patients received either one capsule of the drug combination or one capsule of fl uconazole as a single drug to be swallowed with the evening meal of the fi rst day. In an attempt to prevent reinfection from the partner, each patient also received one tube of ketoconazole cream (Mycoral ® ) to be used by the patient's partner. Patients were advised to refrain from sexual intercourse until the follow-up visit (day 8) or if sexual intercourse was unavoidable, the partners were asked to use a condom or the ketoconazole cream prior to the intercourse. Use of any other antimycotic, either oral (including herbal medicine) or topical (including vaginal medications or douches of potassium permanganate or betel leaves) was prohibited during the study. Patients were advised on methods of hygiene to prevent the spread of their infection. They should have their own towel and toilet equipment, cut their nails, and not using water in the public toilet.
At the follow-up visit (day 8), pelvic examinations were again performed, and vaginal smear and vaginal swab were taken.
Mycological examination was performed on vaginal swab which was inoculated on Sabouraud chloramphenicol agar, or its equivalent, for culture of Candida, examined after 48 hours of incubation at 37 o C. Vaginal smear was also examined by direct microscopy at the same time as the swabbing. These examinations were carried out at baseline (day-1) and at after-treatment (day-8) visits.
Signs and symptoms of VC, consisting of 4 signs (vulvar erythema, edema, fi ssures and tenderness) and 4 symptoms (vaginal discharge, vulvar itching, burning and irritation), were recorded for their presence or absence by the investigator at each visit : baseline (day 1) and followup (day 8). The presence or absence of these symptoms of VC were also recorded by the patients themselves every day on the diary card provided. Any adverse events reported were noted in the case report form.
Assessments
For inclusion in the effi cacy analysis, a patient must be symptomatic and must have a Candida positive microscopic smear at the baseline visit, which were subsequently confi rmed by a positive culture for Candida.
The primary effi cacy endpoint was the mycological cure, i.e. complete eradication of baseline Candida, indicated by both negative culture and microscopy from vaginal swab and vaginal smear on day-8. The secondary effi cacy endpoints were the clinical cure (the disappearance of all signs and symptoms of VC on day 8), the total cure (the clinical cure and the mycological cure on day 8), and the rate of total disappearance of symptoms of VC from the patient diary cards.
Sample size
Sample size was estimated based on the mycological cure (the primary endpoint) by fl uconazole, which was around 85%. 7 The present study was designed to show that the effi cacy of ketoconazole 100 mg and fl uconazole 40 mg combination was not inferior compared to fl uconazole 150 mg. A total number of 194 patients were required when the non-inferiority margin was determined to be 15%, with a statistical power of 90% and one-sided signifi cance level of 0.05 was used.
Data analyses
Besides descriptive statistics, X 2 or Fisher exact test was used to compare the response rates (mycological, clinical and total cure) in both treatment groups (keto-fl uco vs fl uco). Mann-Whitney test was used to compare the time to complete relief of symptoms between the 2 groups.
For safety analysis, adverse events, whether considered related or unrelated to the study drug by the investigator, were listed with their respective incidences.
RESULTS
Patients
A total of 213 patients were screened and 48 patients were either ineligible to be included in the study or loss to follow up after visit 1, and hence were excluded from evaluation. Among the remaining 165 patients who returned for visit 2, 39 patients did not have Candida at baseline (negative baseline culture). Therefore, there were 165 patients eligible for safety evaluation, but only 126 patients were eligible for effi cacy evaluation. The demographics and baseline characteristics of the safety population are presented in Table 1 . The mean age of patients in both groups were similar, around 34 years. The current VC (> 3 episodes in the previous year) were also similar in both groups, around 23%.
Effi cacy
Among the 126 patients who were eligible for effi cacy, 60 patients received ketoconazole-fl uconazole combination and 66 patients received fl uconazole. The mycological eradication rate (from vaginal smear and vaginal swab on day 8) are presented in Table 2 .
The mycological cure in the ketoconazole-fl uconazole group was somewhat higher than in the fl uconazole group (74.5% versus 70.2%, calculated from the number of patients with available mycological culture), but the difference was not signifi cant. The disappearance of all or partial signs and symptoms on day 8 (clinical cure or improvement) are presented in Table 2 .
The clinical cure was the same in both groups (50.0%), also the favourable clinical response was similar in both groups (98.3% versus 100.0%).
The total cure (the mycological cure and the clinical cure) on day 8 are shown in Table 2 .
The total cure in both groups were similar, 49.1% in ketoconazole-fl uconazole group, and 47.4% in fl uconazole group.
Keto-Fluco combination Fluconazole
Number The time to complete relief of symptoms can be seen in Table 3 . The mean time to complete relief of symptoms were also not different between the 2 groups, 4.8 days and 4.4 days.
Safety
Adverse events were found in 5 patients, 3 patients in the ketoconazole-fl uconazole group (3.5%), and 2 patients in fl uconazole group (2.5%) (see Table 4 ). No patient discontinued therapy due to adverse event and no serious adverse event was encountered in this study. 
DISCUSSION
The results of the present study showed that the effi cacy of ketoconazole 100 mg and fl uconazole 40 mg combination was not inferior to that of fl uconazole 150 mg in the treatment of proven VC. Since the combination of ketoconazole and fl uconazole was a new combination that never existed before, we cannot make comparison of its effi cacy with previous studies. Table 3 . Days to complete resolution of symptoms of VC Table 4 . Adverse events in keto-fl uco and fl uconazole groups However, the history of a single oral dose of 150 mg fl uconazole for the treatment of VC was well-known.
Reyes et al. 8 reviewed 14 noncomparative and 14 comparative clinical studies conducted in Europe, Asia, Africa, and Latin America from 1982 to 1992, the safety and effi cacy of a single oral dose of fl uconazole 150 mg for treating VC. A total of 4,942 patients were treated, 3,729 with fl uconazole, and 1,213 with comparative agents. At short-term follow-up (6 to 14 days after treatment began), the mycological eradication was 85% (range 76-98%) in 2,307 mycologically evaluable patients, and the favorable clinical response was 94% (range 88-100%) in 3,729 evaluable patients. 8 In one of the largest comparative study (versus itraconazole), the favorable clinical response at short-term evaluation was 94% in fl uconazole group, consisting of clinical cure 71% and clinical improvement 23%. In 1995, Sobel et al. 11 repeated the single dose fl uconazole for VC study, compared to clotrimazole topical therapy. The mycological cure in 182 patients receiving fl uconazole at short-term (14-day) evaluation was 77% (81% in patients with < 4 episodes of vaginitis in the prior year, and 63% in patients with recurrent VC, i.e. > 4 episodes), while the clinical response was 94% (73% cured, 21% improved). The 73% clinical cure consisted of 78% in patients with < 4 episodes of vaginitis in the prior year and 58% in patients with recurrent VC.
11
According to Sobel 12 in 1992, there were no published reports of resistance in Candida albicans isolates to azole therapy (either topical or systemic) in VC, despite of long-term daily low dosage or cyclical therapy with ketoconazole or monthly single oral dose therapy with fl uconazole.
12 Ten years later, in 2002, Sobel found that 96% of 393 Candida albicans isolates from complicated candidal vaginitis were still highly susceptible to fl uconazole (MICs < 8 mcg/mL), and therefore susceptibility testing for these women were regarded unjustifi ed. 13 In 2004, Sobel found no fl uconazole resistance among 401 Candida albicans isolates recovered from women with recurrent vulvovaginitis, who were maintained with fl uconazole therapy.
14 These fi ndings were supported by Mohanty et al. 15 in 2007 who found a low prevalence of fl uconazole resistance in vaginal Candida isolates (10%) at a rural community in India, and therefore use of fl uconazole may be continued for empirical therapy of uncomplicated candidal vulvovaginitis in the community.
In the present study, the mycological cure by fl uconazole (70.2%) was somewhat lower but not statistically different from that by ketoconazolefl uconazole combination (74.5%), and also from that by fl uconazole in published reports (the lowest was 76%). 8, 10 This sustained effi cacy of a single dose fl uconazole for the treatment of VC may be due to the sustained susceptibility of Candida albicans to fl uconazole, as already demonstrated by Sobel et al. 13, 14 and Mohanty et al.
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The clinical response was found similar for both fl uconazole and ketoconazole-fl uconazole combination (98-100%), and much higher than the mycological response (70-75%), but different from the published reports in the proportion of clinical cure and improvement. In the present study, the clinical cure was only 50% for both treatments, while in published reports it was around 70%. 9, 11 This discrepancy may be due to the subjective evaluation of clinical response which is diffi cult to standardize. Sobel et al. in 1995 11 differentiated the mycological cure rate and clinical cure rate in recurrent VC and nonrecurrent VC, in which the cure rates in recurrent VC were much lower than those in non-recurrent VC. In the present study, the number of patients with recurrent VC was too small (8 in fl uconazole group and 10 in keto-fl uco group) to make comparison with non-recurrent VC.
The time to complete relief of symptoms were the same for both treatment groups, with a median of 4 days and a mean of 4 to 5 days. Previous studies showed that the median time for complete symptom relief for fl uconazole was 3 to 4 days. 8, 9 The incidence of adverse events in patients treated with fl uconazole 150 mg single dose was around 7% to 10%, mostly of mild severity, and the most common were nausea and headache. 2, 8 Lower incidence with the same pattern of adverse events was found in the present study.
In conclusion, the present study showed that the effi cacy and safety of ketoconazole 100 mg and fl uconazole 40 mg combination was not inferior compared to those of fl uconazole 150 mg in single doses for the treatment of vaginal candidiasis. Meanwhile, the effi cacy of fl uconazole 150 mg single dose in the present study was somewhat lower compared to its performance in the previous studies.
